Desk›Healthcare› IOL Chemicals & Pharmaceuticals Ltd
IOL Chemicals & Pharmaceuticals Ltd
BSE 524164 · NSE IOLCP · ISIN INE485C01029 · Group B · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹193.05
+3.76%
BSE close, 28 August 2026
₹5,666.55 cr
29.4 cr shares · Small cap
₹2,135.88 cr
as published
33.7× · 3.42×
EPS ₹5.73 · BV ₹56.45
2,319.06 / 137.72
₹ cr, as filed
29
5 selected · 17%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -1.4% |
|---|---|
| Against 52-week low | +187.5% |
| Day change | +3.76% |
| Size band | Small cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹5.73 |
|---|---|
| Price / earnings | 33.69× |
| Price / book | 3.42× |
| Book value — derived, price ÷ P/B | ₹56.45 |
| Return on equity | 10.14% |
| Operating margin | 14.77% |
| Net margin | 8.53% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 10.15%
- ROE as published
- 10.14%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 756.26 | 64.48 | 2.20 | 14.77% | 8.53% |
| Mar-26 · Q | 619.45 | 53.18 | 1.81 | 15.22% | 8.59% |
| FY25-26 | 2,319.06 | 137.72 | 4.69 | 12.04% | 5.94% |
Quarter on quarter
- Revenue, quarter on quarter
- +22.1%
- Net profit, quarter on quarter
- +21.2%
- Operating margin, quarter on quarter
- -45 bps
Disclosure profile 29 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 1 |
| Concall Transcript | 1 |
| Investor Presentation | 1 |
| Press Release | 1 |
| Results | 1 |
| Selected sub-total | 5 |
| Procedural | |
| Analyst / Investor Meet | 8 |
| General | 5 |
| AGM / EGM | 3 |
| Newspaper Publication | 3 |
| Annual Report | 1 |
| BRSR | 1 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| Trading Window | 1 |
| Procedural sub-total | 24 |
| Total | 29 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
29 filings · 5 selected · busiest 2026-08-07
Filing rhythm · the twelve most recent
2026-09-022026-10-07
SelectedProcedural
Filings
29 in the window · 8 earlier on record
-
7 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 75(5) of SEBI (DP) Regulations
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
25 September 2026 ·
Grant Of Certificate Of Suitability (CEP) For Fenofibrate - Process II
CEP for Fenofibrate - Process II
Company Update / General View filing →
-
25 September 2026 ·
Closure of Trading Window
Intimation of Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
23 September 2026 ·
EU-REACH Registration For Triacetin
EU-REACH Registration for Triacetin
Company Update / General View filing →
-
23 September 2026 ·
Analyst / Investor Meet - Intimation
Schedule of Analyst/Institutional Investor Meeting
Company Update / Analyst / Investor Meet View filing →
-
23 September 2026 ·
Analyst / Investor Meet - Intimation
Schedule of Analyst/Institutional Investor Meeting
Company Update / Analyst / Investor Meet View filing →
-
21 September 2026 ·
Dispatch Of Reminder Letter To Shareholders To Update KYC
Dispatch of Reminder letter to Shareholders to Update KYC
Company Update / General View filing →
-
17 September 2026 ·
Analyst / Investor Meet - Outcome
Transcript of Business Update Call with Investors and Analysts
Company Update / Analyst / Investor Meet View filing →
-
11 September 2026 ·
Analyst / Investor Meet - Outcome
Audio Recording of Business Update Call with Investors and Analysts
Company Update / Analyst / Investor Meet View filing →
-
10 September 2026 ·
Analyst / Investor Meet - Intimation
Business Update Conference Call to discuss the Company's recent business developments and strategic growth initiatives with investors and analysts
Company Update / Analyst / Investor Meet View filing →
-
9 September 2026 ·
Expansion Of Ibuprofen Capacity, New CDMO Business For Pharmaceutical Formulations And Dedicated Specialty Chemicals Manufacturing Facility
Expansion of Ibuprofen Capacity, New CDMO Business for Pharmaceutical Formulation and Dedicated Specialty Chemicals Manufacturing Facility
Company Update / General View filing →
-
2 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Voting Results and Scrutinizer's Report
AGM/EGM / AGM View filing →
-
2 September 2026 ·
-
26 August 2026 ·
Analyst / Investor Meet - Intimation
Schedule of Analyst/Institutional Investor Meeting
Company Update / Analyst / Investor Meet View filing →
-
20 August 2026 ·
Earnings Call Transcript
Earning Call Transcript
Company Update / Earnings Call Transcript View filing →
-
18 August 2026 ·
Newspaper Publication
Submission of Newspaper Publication
Company Update / Newspaper Publication View filing →
-
13 August 2026 ·
Analyst / Investor Meet - Outcome
Audio Recording of Analysts/Investors Call pertaining to the Financial Results Q1- FY2027
Company Update / Analyst / Investor Meet View filing →
-
12 August 2026 ·
-
11 August 2026 ·
Communication To The Shareholders Regarding AGM Notice And Annual Report For The Financial Year 2025-26
Communication to the Shareholders regarding AGM Notice ansd Annual Report for the Financial Year 2025-26
Company Update / General View filing →
-
11 August 2026 ·
Newspaper Publication
Submission of newspaper publication of unaudited Financial Results for the quarter ended 30th June 2026
Company Update / Newspaper Publication View filing →
-
10 August 2026 ·
Press Release / Media Release
Press Release- Financial Results for the quarter ended 30th June 2026
Company Update / Press Release / Media Release View filing →
-
10 August 2026 ·
Outcome Of The Board Meeting And Submission Of Unaudited Financial Results Of The Company For The Quarter Ended 30Th June 2026
Submission of Unaudited Financial Results of the Company for the quarter ended 30th June 2026
Result / Financial Results View filing →
-
10 August 2026 ·
Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Unaudited Financial Results Of The Company For The Quarter Ended 30Th June 2026
Outcome of the Board Meeting and submission of Unaudited Financial Results of the Company for the quarter ended 30th June 2026
Board Meeting / Outcome of Board Meeting View filing →
-
7 August 2026 ·
Analyst / Investor Meet - Intimation
Schedule of analyst / investor conference call - Q1 FY27
Company Update / Analyst / Investor Meet View filing →
-
7 August 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
Submission of BRSR FY 2025-26
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
7 August 2026 ·
Submission Of Notice Of The 39Th Annual General Meeting
Notice of 39th Annual General Meeting
AGM/EGM / AGM View filing →
-
7 August 2026 ·
Reg. 34 (1) Annual Report.
Submission of Integrated Annual Report for FY 2025-26
Others / Reg. 34 (1) Annual Report View filing →
-
3 August 2026 ·
Board Meeting Intimation for Notice Of Board Meeting
IOL Chemicals & Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve the Un-audited ....
Board Meeting / Board Meeting View filing →
-
3 August 2026 ·
RSS feed for IOL Chemicals & Pharmaceuticals Ltd · the 50 most recent filings